Skip to main content
2024 CNSF Congress Main banner
Neuro|News Annual Edition
Final Program


Calendar-of-Events
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Evaluation

Industry Supported Session

Lunch 'n Learn: Rare neurological diseases: Advancements in the treatment of gMG, NMOSD, and NF1

Tuesday, May 21, 2024
12:00 PM – 1:30 PM EST
Location:CF: Ballroom

Audience:

Adult Neurologist, Child Neurologist, Neurosurgeon, Neuroradiologist, Neurophysiologist, Resident, Fellow, Nurses with interest in topic

Learning Level:

Basic (Resident, New Information), Intermediate (Practicing Physician), Advanced (Special Interest, Higher Level Discussion)

Learning Format:

Case studies, Forum/panels, Lecture/plenary method, Question and answer sessions, Seminar

CanMEDs Roles:

Medical Expert, Scholar, Communicator, Collaborator, Leader, Health Advocate, Professional

Review new advances and real-world management of 3 rare neurological diseases. Ravulizumab in the treatment of complement mediated diseases: gMG and NMOSD. Selumetinib in the treatment of patients with NF1 PN. Revisiting “the patient”, treatment goals, and meaningful benefits to patients.

This program was developed by the CNSF and Alexion and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.

Learning Objectives:

  • Discuss the real-world management and evolving evidence for Ravulizumab in the Treatment of gMG
  • Evaluate the Efficacy, Safety and Application of Ravulizumab in the treatment of Aquaporin-4-Positive NMOSD
  • Discuss the NF1 burden of disease and evidence for Selumetinib in the treatment of patients with NF1 PN

Presentations:

  • 12:00 PM – 12:40 PM EST
    Treating Complement-Mediated Diseases in the Real World. When Advancement Meets Results. Part 1: gMG

    Faculty: Mike Nicolle

  • 12:40 PM – 1:10 PM EST
    Treating Complement-Mediated Diseases in the Real World. When Advancement Meets Results. Part 2: NMOSD

    Faculty: Mark Freedman

  • 1:10 PM – 1:30 PM EST
    NF1 Plexiform Neurofibromas: Burden of Disease, Unmet Need, and the Role of Selumetinib Treatment

    Faculty: Vijay Ramaswamy